The full detailed presentation of ABBV/ENTA’s six phase-3 HCV trials for the initial NDA (the first six trials listed in #msg-93647264) is planned for EASL in Apr 2014, according to ABBV’s CS webcast today. Top-line data from these trials will be released as the data become available, starting with SAPHIRE-1 and SAPHIRE-2 before 2013 year-end.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.